Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.

Breast cancer research and treatment - 1 May 2014

Hertz Daniel L, Roy Siddharth, Jack John, Motsinger-Reif Alison A, Drobish Amy, Clark L Scott, Carey Lisa A, Dees E Claire, McLeod Howard L

Abstract excerpt

The development of paclitaxel-induced peripheral neuropathy (PIPN) is influenced by drug exposure and patient genetics. The purpose of this analysis was to expand on a previous reported association of CYP2C8*3 and PIPN risk by investigating additional polymorphisms in CYP2C8 and in hundreds of other genes potentially relevant to paclitaxel pharmacokinetics. Clinical data was collected prospectively in an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C8

Share to Drug Resistance, Neoplasm

Share to Genetic Heterogeneity

Share to Oligonucleotide Array Sequence Analysis

Share to Paclitaxel

Share to Peripheral Nervous System Diseases

Source

Open in PubMed Open full text

Identifiers

PMID: 24706167
DOI: 10.1007/s10549-014-2910-1
PMCID: PMC4256153

Genes

ABCG1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.PMID 24706167Read ↗

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.Semantic proximity Read ↗

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.Semantic proximity Read ↗

Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.Semantic proximity Read ↗

Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting NeuropathySemantic proximity Read ↗

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.Semantic proximity Read ↗

Identification of Rare Variants in Candidate Genes Associated with Chemotherapy-Induced Peripheral NeuropathySemantic proximity Read ↗

ABCB1 Single Nucleotide Polymorphism Genotypes as Predictors of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer.Semantic proximity Read ↗

Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.Semantic proximity Read ↗

Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance).Semantic proximity Read ↗

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.Semantic proximity Read ↗

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.Semantic proximity Read ↗

The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.